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Objective To investigate the existence of distinct classes of gout flare trajectories and 
compare their gout-specific, comorbid and sociodemographic characteristics. 
Method In a prospective cohort study, adults with gout registered with 20 general practices 
self-reported the number of gout flares experienced at baseline and after 6, 12, 24, and 36 
months via postal questionnaires. Latent class growth analysis (LCGA) was used to identify 
distinct gout flare trajectory classes.  Statistical criteria and clinical interpretability were used 
to decide the optimal number of classes.  Baseline comorbidities, medications, 
sociodemographic and gout-specific characteristics of members of each class were described.     
Results 1164 participants (mean age 65.6 years (SD 12.5), 972 (84%) male) were included.  Six 
latent gout flare trajectory classes were identified: ‘frequent and persistent’ (n=95), ‘gradually 
worsening’ (n=276), ‘frequent then improving’ (n=14), ‘moderately frequent’ (n=287), 
‘moderately frequent then improving’ (n=143), and ‘infrequent’ (n=349).  The ‘frequent and 
persistent’ trajectory had the most class members classified as obese and, along with the 
‘gradually worsening’ class, the highest proportion who were socio-economically deprived.  
The ‘frequent and persistent’, ‘gradually worsening’ and ‘frequent then improving’ classes 
had the highest proportions of class members with an eGFR<60 mL/min/1.73m2.  The 
‘Infrequent’ gout flare class was associated with more frequent allopurinol use and lower 
urate levels.  
Conclusions Six distinct gout flare trajectories were identified.  Infrequent flares were 
associated with allopurinol use and lower serum urate levels supporting the use of urate-
lowering therapy to reduce flare frequency. The characteristics of flare trajectory classes 






Gout is the most common inflammatory arthritis affecting 3.8 % of the US population.[1] 
Despite its high prevalence and the availability of effective urate-lowering therapy, gout is 
often sub-optimally managed.[2-4] The clinical hallmark of gout is extremely painful acute 
inflammatory flares, which are typically sudden in onset and characterised by swelling, 
erythema, heat and tenderness of the affected joint.[5-7]   Frequent flares are associated with 
poorer health-related quality of life [8], functional disability [9-10], higher use of healthcare 
resources [11-13], and lower work productivity.[12] Whilst it is well recognised that gout 
flares are recurrent, there is a paucity of literature quantifying flare frequency over time and 
risk factors for frequent flares are not well described. Existing studies have mostly 
investigated the risk of a recurrent flare in a follow-up time-period.[14-18] A different 
approach is to describe symptom trajectories over time, using follow-up data from multiple 
time-points, and allocating individual participants to specific trajectory classes. This approach 
has been used to investigate pain, activity limitation, psychological factors, and comorbidities 
in various musculoskeletal and rheumatological conditions.[19-24] However, to our 
knowledge, trajectories of gout flares have not been described.  Thus, the objective of this 
study was to investigate the existence of distinct classes of gout flare trajectories in a 
prospective cohort of people living with gout in primary care and compare the gout-specific, 









Patients and methods 
Study design & population 
This study was a three-year prospective cohort study based in primary care in the West 
Midlands, UK. [25]  
Adults aged >18 years registered with one of twenty participating general practices and who 
had consulted with gout or received a prescription for allopurinol or colchicine in the 
preceding two years were mailed a baseline questionnaire.  Gout consultations were 
identified by Read codes, a coded hierarchy of clinical codes based on ICD-9 codes, which is 
widely used for diagnostic coding in primary care in the UK.  Participants provided written 
informed consent to participate and were also asked to provide consent for the practice to 
provide the research team with information about comorbidities, medication, and 
investigations from their medical record.  Ethical approval for this cohort study was granted 
by North West-Liverpool East Research and Ethics Committee (REC) reference 12/NW/0297. 
 
Data collection  
Questionnaires were mailed at baseline (October/November 2012), and then at 6, 12, 24 and 
36 months. Participants were asked to self-report the number of self-defined gout flares (0, 
1, 2, 3, 4 or >5) they had experienced in the last 12 months (in the baseline, 24- and 36-month 
questionnaires) or 6 months (in the 6- and 12-month questionnaires) using the question “How 
many attacks of gout have you had in the last 12 months/6 months?”.  Baseline characteristics 
of participants were obtained from both questionnaire responses and medical record review. 
Gout-specific (age of gout onset, history of oligo- or polyarticular flares (ever)), comorbidities, 
sociodemographic (age, gender, attendance at further education), and anthropometric 




duration was calculated by subtracting age at gout diagnosis from current age. The total 
number of comorbidities was the sum of comorbidities self-reported in the baseline 
questionnaire (diabetes, hypertension, hyperlipidaemia, myocardial infarction, angina, 
cerebrovascular accident, transient ischaemic attack, renal failure, renal calculi). BMI was 
calculated using self-reported weight and height. Neighbourhood deprivation was 
determined from the rank of the indices of multiple deprivation (IMD) using participant postal 
codes.[26] IMD ranks (neighbour deprivation) were categorised into tertiles.  Extraction of 
data concerning presence of tophi (Read code or clinician free-text entry), serum urate level 
(highest recorded), estimated glomerular filtration rate (eGFR) and prescription of allopurinol, 
colchicine and diuretics were obtained from the medical record over the period two years 
prior to baseline.  
 
Statistical analyses  
Attrition bias was investigated by comparing comorbidities, medication, socio-demographic 
and gout-specific characteristics at baseline between responders and non-participants at 
each of the five time-points. Latent class growth analysis (LCGA) was used to identify distinct 
trajectories of gout flares, enabling classes of people with similar trajectories to be 
identified.[27-28] LCGA was undertaken using Mplus version 8.1 using full information 
maximum likelihood (FIML). FIML deals with missing data by using maximum likelihood 
estimation and all available outcome data for each participant, in order to derive parameter 
estimates for the model, to increase precision and reduce bias [29-30].  Consequently, all 
available data were used, including all participants who self-reported the number of gout 
flares experienced on at least one time-point. Following preliminary analysis involving latent 




(linear, quadratic, ordinal, zero-inflated Poisson, negative binominal models), a quadratic 
ordinal model was selected as the most appropriate model for the LCGA.  After fitting a one-
class quadratic ordinal LCGA model, the number of trajectory classes was increased 
sequentially.  The statistical fit of each model was assessed by comparing Bayesian 
Information Criteria (BIC), Akaike Information Criteria (AIC), Bootstrapped Likelihood Ratio 
Test (BLRT), Lo-Mendell–Rubin Likelihood Ratio Test (LMR-LRT), Entropy, and the number of 
members per class (%) based on the most likely class membership. Lower values for BIC and 
AIC indicate a better fitting model.[28, 31-32]  A significance level  of  p<0.05 for BLRT and 
LMR-BLT indicates a better fit compared with a model with one fewer class. [32-34] Cut-offs 
of 1.0 (perfect), 0.8 (high), 0.6 (medium), and 0.4 (low) have been proposed for entropy [35], 
and class sizes smaller than 1% of the total cohort are considered to be insufficient.[27, 34]  
Trajectory classes were plotted with the probability of experiencing two or more gout flares 
because experiencing two or more gout flares in 12 months indicates recurrent flares where 
urate-lowering therapy would be particularly indicated.[36-38]  After determining the optimal 
number of trajectory classes the baseline gout-specific, comorbid, sociodemographic and 
gout-specific characteristics of each trajectory class were compared descriptively using SPSS 
version 24. Sensitivity analyses were undertaken to compare the optimal number of 
trajectory classes selected in different data-sets with varying degrees of missing data 
(participants who reported gout flare frequency at (i) three or more time-points and (ii) all 
five time-points).  Multiple imputation (MI) was undertaken on the descriptive characteristics 
of the latent classes using Stata 14, to ascertain whether the characteristics of the classes 







1184 participants responded to the baseline questionnaire (adjusted response 65.9%; 
questionnaire responders as a proportion of those eligible for mailing); mean age was 65.6 
(12.5) years and 990 (83.6%) were male.[39]  Follow-up questionnaires were returned by 818, 
721, 696 and 605 participants at 6, 12, 24 and 36 months respectively (supplementary figure 
S1). Continued responders tended to be younger, male, have longer gout duration, more 
commonly live in less deprived areas, have attended further education, and have a 
prescription of allopurinol, but report fewer gout flares at baseline than non-participants 
(table 1). 1164 participants self-reported the number of gout flares experienced on at least 
one time-point and were included in the LCGA.   Their baseline characteristics did not appear 
to differ from the full cohort. 1079 participants (91%) consented to information about 
comorbidities, medication, and investigations being made available from their medical record 
review (supplementary figure S2) 
 
Trajectories 
On LCGA, the six-class solution was considered the best fit as this returned the lowest BIC, a 
statistically significant BLRT, and medium to high entropy. All class sizes were larger than 1% 
of the total number of participants included in the analysis (table 2). The trajectories of the 
six-class solution also had a plausible clinical interpretation. One gout flare trajectory class 
had a high probability of two or more flares at each time-point and was termed ‘frequent and 
persistent’ (n=95) (figure 1).  The smallest class (n=14) displayed a sharp decrease in the 
probability of two or more gout flares after six months (‘frequent then improving’). Further 
classes showed an increasing probability of two or more gout flares over time (‘gradually 




frequent’, n=287), and a decrease in the probability of two or more gout flares after baseline 
(‘moderately frequent then improving’, n=143). The largest class (n=349) had a very low 
probability of two or more gout flares at each time-point (‘infrequent’).   The sensitivity 
analyses in participants who reported gout flare frequency on (i) at least three time-points 
and (ii) all five time-points confirmed the six-class solution as the optimal model 
(supplementary tables S1 and S2) and revealed similar trajectory shapes for the six-class 
model in each data set.  
 
Baseline characteristics of trajectory class members 
The ‘frequent and persistent’, and ‘gradually worsening’ classes had the highest proportion 
of class members classified as most socioeconomically deprived (41.1%, 40.6% respectively) 
(table 3).  Fewer participants in the ‘frequent and persistent’, ‘frequent then improving’ and 
‘gradually worsening’ reported attending further education (11.6%, 7.1%, 15.2%) compared 
with other classes.  Obesity was most common in the ‘frequent and persistent’ class (43.2%).   
The ‘frequent and persistent’, ‘frequent then improving’ and ‘gradually worsening’ classes 
had higher proportions of class members with an eGFR<60 mL/min/1.73m2 (30.5%, 42.9%, 
30.1% respectively) compared with other classes (table 3). The ‘frequent then improving’ class 
had the highest proportion of class members with a prescription for diuretics in the two years 
prior to baseline (42.9%).  The ‘frequent and persistent’ and ‘frequent then improving’ classes 
had more members reporting oligo/polyarticular flares (68.4 and 78.6% respectively) and with 
a prescription for colchicine in the 2 years prior to baseline (46.3% and 50% respectively).  The 
‘gradually worsening’ class had the highest mean maximum serum urate level (480.5 µmol/L). 
Although tophi were infrequently recorded, they were most frequent in the ‘frequent then 




the highest proportion of class members with a prescription for allopurinol (73.4%) (table 3) 
and reporting allopurinol use at baseline (73.0%) (supplementary table S3), the lowest mean 
maximum serum urate level (377.1 µmol/L) and the longest mean disease duration (15.6 
years). The ‘infrequent’ class had a greater proportion of class members with a serum urate 
<360 µmol/L (46.5%) and <300 µmol/L (24.2%) compared with other classes (table 3).  
The proportion of missing data for these baseline characteristics is shown in supplementary 
table S4.  The baseline characteristics of participants in separate trajectory classes did not 
change following multiple imputation (supplementary table S5). 
 
Allopurinol use over-time 
The proportion of participants taking allopurinol in the ‘frequent then improving’ class 
increased from 29% at baseline to 73% at 36 months (supplementary table S3) but there was 
little change in the median self-reported allopurinol dose either overall or in any class.   
 
Discussion 
To our knowledge, this is the first study to use LCGA to explore the existence of gout flare 
trajectories over time.  We identified six distinct trajectory classes which displayed a range of 
patterns in gout flares over time including classes with a high probability of flares at all time-
points, an increasing probability of flares over time, a moderate probability of flares, a 
consistently low probability of flares, and two classes which displayed a decreasing probability 
of flares over time.  
Whereas previous studies have examined the risk of having recurrent flares over a follow-up 
period [14-18], this is the first study to use LCGA to describe gout flare trajectories using data 




Our findings are consistent with trajectories of disease activity [20] and joint pain [21,24] 
reported in other musculoskeletal conditions which have also displayed persistent, 
worsening, moderate, infrequent, and improving patterns of change.  The distinct 
characteristics of different gout flare classes identified in this study are also consistent with 
factors associated with gout flares reported in previous studies.  We found that participants 
in more frequent flare trajectories were commonly characterised by socioeconomic 
deprivation, non-attendance at further education, obesity, and chronic kidney disease. We 
have previously shown in a cross-sectional analysis using baseline data from this cohort that 
both deprivation and non-attendance at further education are associated with more frequent 
flares.[41] Both obesity and chronic kidney disease were found to be independent risk factors 
for first post-diagnosis recurrent flare in a large prospective study in UK general practice.[14] 
More frequent flares were also associated with obesity in a cross-sectional community study 
[15] and increase in BMI in the prospective Multiple Risk Factor for Intervention trial (MRFIT) 
dataset.[16] We also found that the ‘frequent then improving’ class had the highest 
proportion prescribed a diuretic although this finding should be interpreted with caution in 
view of the small class size. Diuretic use has been associated with increased risk of gout flares 
in an internet case-crossover study [17] and a cohort study using medical service data from 
Kaiser Permanente.[18]  The higher proportion of class members in the frequent classes who 
reported oligo/polyarticular flares provides face validity that classes with frequent flares had 
more severe gout.  
The finding that over a third of participants had self-reported gout flares which followed a 
persistently frequent or worsening trajectory is consistent with other studies reporting 
suboptimal management of gout in primary care.[42, 2]  The ‘gradually worsening’ class had 




a serum urate level above 360µmol/L (6mg/dL) is a risk factor for gout flares.[43-44, 11, 45-
47]  Furthermore, the ‘infrequent flare’ class had the lowest mean serum urate level, more 
participants with a serum urate at target (<300 µmol/L and <360 µmol/L) and the highest 
proportion prescribed allopurinol, supporting the beneficial effects of urate-lowering therapy 
on gout flare frequency.   
Strengths of this study include the study size and primary care setting, ensuring 
generalisability of our findings.   The selection of the optimal number of trajectory classes was 
based on both statistical and clinical considerations. The BIC and BLRT have been identified 
as the better performing information criteria and likelihood ratio test respectively in 
comparison to other indices [32] and the six-class model yielded the lowest BIC and a 
statistically significant BLRT.  Growth mixture modelling (GMM) was trialled as an alternative 
to LCGA, however both the linear and quadratic slopes of the GMM had to be fixed to zero in 
order for the model to run, GMM took a prolonged period of time to run, and bootstraps for 
the BLRT did not converge for models beyond two classes. Hence, LCGA was used for this 
analysis. 
The limitations of the study include the small size of the ‘frequent then improving’ class, 
representing 1.2% of the cohort (14 participants). This only just exceeds the minimum 
recommended class size of 1%. [27, 34]  However, in view of the very distinctive and clinically 
relevant trajectory with a high probability of gout flares initially which then reduced after six 
months, the six-class solution was retained. Since participants were identified either by a 
Read code for gout or a prescription for allopurinol or colchicine, it is possible that we 
included people who were prescribed allopurinol or colchicine for other indications. However, 
no participants identified by a prescription only had a Read code for other indications for 




S2). Whilst 400 participants identified by a prescription only did not consult for gout during 
the study period, it is plausible that patients treated with allopurinol would not have a flare 
severe enough to lead to consultation over a lengthy period. A further caveat is that the 
diagnosis of gout was based on a GP diagnosis rather than the gold standard of monosodium 
urate crystal identification, however joint aspiration is performed infrequently in primary care 
and Read-coded diagnosis has been shown to have a sensitivity and specificity of over 
90%.[48]  Flares were self-reported rather than using a validated flares definition such as that 
by Gaffo et al [49], risking over-ascertainment, although self-reported flares have been widely 
used in clinical studies of this nature. [15-17,50]  Finally, we did not collect data about the 
joint sites affected by flares. 
The observations concerning the characteristics of members of the trajectory classes could 
provide an opportunity to target interventions and subsequently improve patient care.  For 
example, education and resources could be tailored and prioritised to participants with 
characteristics associated with membership of the worst trajectories, such as socioeconomic 
deprivation, obesity or chronic kidney disease.    
This analysis was intentionally exploratory in nature, due to the paucity of previous research 
investigating gout flare trajectories. As this is the first investigation of latent gout flare 
trajectories, it would be prudent to investigate gout flare trajectories in other cohorts.   
In conclusion, this is the first time LCGA has been used to identify gout flare trajectories 
prospectively over time.  We identified six distinct gout flare trajectory classes, which differed 
by sociodemographic, gout-specific, and comorbid characteristics.  These gout flare trajectory 
classes and their characteristics could provide an opportunity to target interventions and 
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Figure labels and legends 
























 12 Months 
Response 
 24 Months 
Response 



































































































eGFR <60 mL/ 

































































>2 gout flares in previous 
















































History of oligo/ 















Tophi* 25(2.1) 17(2.4) 8(1.7) 13(1.9) 12(2.5) 12(2.0) 13(2.2) 
















Serum urate <360 
















Serum urate <300 















n(%) unless stated otherwise, * from medical record review in the two years prior to baseline, IMD indices 
of multiple deprivation, obesity = BMI >30 kg/m2, eGFR (estimated glomerular filtration rate) eGFR <60 
indicates chronic kidney disease, serum urate was highest serum urate level recorded in the two years prior 









AIC BIC BLRT LMR-
LRT 
Entropy Number per class (%)  


















2 10096.37 10152.03 P value  
 <0.001 
P value  
<0.001 
 0.703 460/704 
(39.5/60.5) 
  
















5 9799.75 9916.12 P value  
<0.001 
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AIC, Akaike Information Criteria; BIC, Bayesian information criteria; BLRT, Bootstrap likelihood ratio 
test; LMR-LRT, Lo Mendell Rubin likelihood ratio test. 
The lowest BIC and statistically significant BLRT for the six class solution indicated the optimal 
number of classes. 
a model fixed to avoid singularity, warning given that model may not be identified,  b Warning that 
not all of bootstraps converged,        C Warning that some draws had smaller LRT than observed LRT 






Table 3: Baseline characteristics of gout flare trajectory classes  
























Age mean (SD) 
65.6 
(12.5) 







79(83.2) 226(81.9) 11(78.6) 248(86.4) 115(80.4) 293(84.0) 
 
Most deprived 
IMD tertile  
360 
(30.9) 











41(43.2) 97(35.1) 5(35.7) 85(29.6) 47(32.9) 105(30.1) 
 














28(29.5) 74(26.8) 6(42.9) 67(23.3) 41(28.7) 64(18.3) 
 
Gout duration 
mean years (SD) 
11.9 
(12.0) 
11.6(12.3) 11.0(11.6) 7.5(5.9) 9.6(11.2) 9.8(12.3) 15.6(12.3) 
















44(46.3) 97(35.1) 7(50.0) 103(35.9) 48(33.6) 41(11.7) 
 
History of oligo 
/polyarticular 
flares (ever)   
432 
(37.1) 
65(68.4) 132(47.8) 11(78.6) 87(30.3) 44(30.8) 93(26.6) 
Tophi*   
25 
(2.1) 
4(4.2) 8(2.9) 1(7.1) 4(1.4) 4(2.8) 4(1.1) 
 
Serum urate          441.0 














Serum urate            107 













Serum urate†           54 













n(%) unless stated otherwise, * from medical record review in the two years prior to baseline, IMD indices of 
multiple deprivation, obesity = BMI >30 kg/m2, eGFR (estimated glomerular filtration rate) eGFR <60 indicates 
chronic kidney disease,  serum urate was highest serum urate level recorded in the two years prior to baseline. †as 












































































































consenting to medical 
record review 
n=1079 
Identified by allopurinol or 
colchicine prescription 
(without a gout Read code) 
pre-baseline 
n=489 
Read code for other 
condition linked to 
allopurinol use (and no 
gout Read code) 
during pre-baseline or 
follow-up periods 
 
 lymphoma, leukaemia 
n=0  
uric acid renal stones 
n=0 
Gout Read code 
during follow-up  
n=89 
No gout Read code 
and  
no Read code for 
other condition linked  
to allopurinol use  
 during pre-baseline or 











































Table S1: Model fit results for LCGA of gout flare trajectories in participants who reported gout 





AIC BIC BLRT LMR-
LRT 
Entropy Number per class (%)  
based on most likely class 
membership 
1 9202.20 9234.11 - - - 729 
(100) 
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AIC, Akaike Information Criteria; BIC, Bayesian information criteria; BLRT, Bootstrap likelihood ratio 
test; LMR-LRT, Lo Mendell Rubin. 
The lowest BIC and statistically significant BLRT for the six class solution indicated the optimal 
number of classes 
a model fixed to avoid singularity, warning given that model may not be identified, b Warning that 
not all of bootstraps converged,  C Warning that some draws had smaller LRT than observed LRT 





Table S2: Model fit for LCGA of gout flare trajectories in participants who reported gout flare 





AIC BIC BLRT LMR-
LRT 
Entropy Number per class (%)  
based on most likely class 
membership 
1 6017.52 6046.07 - - - 437 
(100) 
       






       






       






       
5
a






       








       
   7
b,c








       
    8
a,b,c









AIC, Akaike Information Criteria; BIC, Bayesian information criteria; BLRT, Bootstrap likelihood ratio 
test; LMR-LRT, Lo Mendell Rubin. 
The lowest BIC and statistically significant BLRT and LMR-LRT  for the six class solution indicated 
the optimal number of classes 
a model fixed to avoid singularity, warning given that model may not be identified, b Warning that 
not all of bootstraps converged, C Warning that some draws had smaller LRT than observed LRT. 








































 Baseline 6 months 12 months 24 month 36 months 
      
Self-reported allopurinol 
use† 
     
All participants  624 (53.6) 466(59.7) 435(60.3) 425(61.2) 377(62.3) 
 




























































‘infrequent’ 255(73.1) 194 (83.6) 170(82.5) 171(84.2) 155(83.8) 
 
Median (IQR) self-reported 
allopurinol dose* 
     


















































































































Table S4: Missing data rates for the baseline variables used to describe the gout flare 
trajectory classes   
 
























Age   
0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
Male  0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
 
Most deprived 
IMD tertile  























































































































































History of oligo 
/polyarticular 
































Serum urate             707 
 µmol/L *                 (60.7) 















n(%) missing items per characteristic, * from medical record review in the two years prior to baseline, IMD 
indices of multiple deprivation, obesity = BMI >30 kg/m2, eGFR (estimated glomerular filtration rate) eGFR 
<60 indicates chronic kidney disease, comorbidities = number of comorbidities self-reported in baseline 




Multiple imputation method 
Multiple imputation (MI) using chained equations was undertaken using Stata 14.  The following 
variables were included in the MI model, auxiliary variables (with no missing data) were age, sex, index 
of multiple deprivation tertile, number of self-reported comorbidities and imputed variables were 
attendance at further education, BMI, eGFR <60 mL /min/1.73m2, diuretic prescription, gout duration, 
>2 Gout flares in previous 12 months, allopurinol prescription, colchicine prescription, history of oligo 
/polyarticular flares (ever), tophi, serum urate. Continuous variables were imputed using predictive 
mean matching (pmm) and dichotomous variables were imputed using logistic regression (logit). 61 
imputations were undertaken for each imputed variable, as serum urate was missing at 61% in this 
cohort. [1] Results were pooled using mi estimate to calculate proportions and misum to calculate 
means, estimates were pooled using Rubin’s rule for pooling. [2] 
 The results of the MI can be found in supplementary table S5.  
 
[1] White IR, Royston P, Wood AM.   Multiple imputation using chained equations: Issues and guidance 
for practice.   Tutorial in Biostatistics 2011; 30: 377–399. 













Table S5: Baseline characteristics of gout flare trajectory classes results from multiple imputation (MI) 
























Age mean (SD) 
65.6 
(12.5) 







79(83.2) 226(81.9) 11(78.6) 248(86.4) 115(80.4) 293(84.0) 
 
Most deprived 
IMD tertile  
360 
(30.9) 





21.8 11.9 15.8 7.1 28.5 18.9 25.5 
 
Obesity  34.5 44.9 37.7 35.7 31.6 34.3 31.6 
 
eGFR <60* mL 
/min/1.73m2  








26.5 32.6 29.8 42.9 26.1 29.1 20.7 
 
Gout duration 
mean years (SD) 
11.8          
(12.0) 
11.5          
(12.3) 
11.1          
(11.6) 






15.3          
(12.2) 
 
>2 Gout flares in 
previous 12 
months 








31.9 51.2 39.9 52.3 38.1 33.8 13.7 
 
History of oligo 
/polyarticular 
flares (ever)   
38.5 68.8 49.8 83.4 31.9 30.8 28.6 
 
Tophi*   2.4 4.2 3.4 7.1 1.6 3.0 1.2 
 
Serum urate          430.9               
 µmol/L *              (114.2) 
mean (SD)            
470.3         
(108.3)  
465.0         
(110.3) 
489.5         
(153.6) 
438.0         
(109.5) 
434.6         
(105.3) 
383.4        
(106.9) 
 
Serum urate         25.7    
<360 µmol/L         
16.8 17.3 9.6 20.2 23.1 41.2 
 
Serum urate         13.9 
<300 µmol/           
4.9 7.9 9.6 12.2 13.2 25.8 
% unless stated otherwise, imputed variable results in bold, * from medical record review in the two years prior to 
baseline, IMD indices of multiple deprivation, obesity = BMI >30 kg/m2, eGFR (estimated glomerular filtration rate) eGFR 
<60 indicates chronic kidney disease , comorbidities = number of comorbidities self-reported in baseline questionnaire,  
serum urate was highest serum urate level recorded in the two years prior to baseline. 
